Exane Derivatives’s Charter Communications CHTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$86.7K Sell
185
-5
-3% -$2.44K 0.05% 275
2022
Q1
$104K Sell
190
-566
-75% -$332K 0.03% 469
2021
Q4
$493K Buy
756
+32
+4% +$21.8K 0.12% 180
2021
Q3
$527K Buy
724
+485
+203% +$368K 0.13% 180
2021
Q2
$170K Sell
239
-17
-7% -$11.4K 0.04% 440
2021
Q1
$158K Sell
256
-1,985
-89% -$1.24M 0.05% 332
2020
Q4
$1.48M Sell
2,241
-129
-5% -$82.1K 0.44% 46
2020
Q3
$1.48M Buy
2,370
+1,546
+188% +$912K 0.43% 48
2020
Q2
$420K Sell
824
-343
-29% -$174K 0.11% 160
2020
Q1
$509K Sell
1,167
-84
-7% -$41.1K 0.14% 124
2019
Q4
$645K Buy
+1,251
New +$576K 0.12% 137
2019
Q1
Sell
-267
Closed -$76.1K 684
2018
Q4
$76.1K Hold
267
0.01% 342
2018
Q3
$86.5K Sell
267
-635
-70% -$194K 0.02% 337
2018
Q2
$269K Buy
902
+602
+201% +$173K 0.04% 231
2018
Q1
$92.5K Buy
+300
New +$105K 0.02% 307

Other funds holding CHTR

Exane Derivatives's CHTR Position: Q2 2022 in Review

Exane Derivatives reduced its Charter Communications (CHTR) stake by 2.6% in Q2 2022, selling an estimated $2.44K and leaving 185 shares worth $86.7K. The position accounts for 0.05% of the portfolio, ranked #275.

Exane Derivatives first reported a position in CHTR in Q1 2018 and has held it in 15 quarters since. The position peaked at $1.48M in Q4 2020. 944 funds tracked by Wall St. Rank hold CHTR as of Q2 2022.

  • Exane Derivatives held 185 shares of Charter Communications worth $86.7K as of Q2 2022.
  • Exane Derivatives sold 5 Charter Communications shares in Q2 2022, an estimated $2.44K.
  • Charter Communications made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #275 holding.
  • Exane Derivatives first reported a position in Charter Communications in Q1 2018 and has held it in 15 quarters since.
  • Exane Derivatives's Charter Communications position peaked at $1.48M in Q4 2020.
  • 944 funds tracked by Wall St. Rank held Charter Communications as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.